Avanir Deal Partly Plugs Otsuka’s Abilify Gap
This article was originally published in PharmAsia News
Executive Summary
While some eyebrows are being raised over the sum Otsuka Pharmaceutical is proposing to shell out for a small U.S. CNS company with only one niche marketed product, the pipeline the deal will bring is being viewed positively by some analysts.